Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5814007 | 0.88 | LMNA (0.45) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL29983795 | 0.86 | GABRR1 (0.48) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL6237469 | 0.86 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL3681337 | 0.86 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL28617289 | 0.86 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL12219258 | 0.86 | GABRR1 (0.48) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL5174591 | 0.86 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL27525813 | 0.86 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL3681340 | 0.86 | LMNA (0.39) | LMNATSHRMMP1MMP2MMP3 | |
| SCHEMBL13210308 | 0.84 | MAPT (0.52) | LMNATSHRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | UBE INDUSTRIES, LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1500642-A1 | 3-SUBSTITUTED OXYGLUTARIC DIESTER COMPOUND, OPTICALLY ACTIVE 3-SUBSTITUTED OXYGLUTARIC MONOESTER COMPOUND, AND PROCESSES FOR PRODUCING THESE | Ube Industries, Ltd. (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | OGDH, GLUL, ADSL | LMNA 4022/4885TSHR 3921/4885MMP1 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.